Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Aaa Aaaaaa Aaaaa A 115.67 +22.22% ...

As of 23 December at 1:01:52 pm GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 27 December at 12:58:04 pm GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 2:48 PM EST. Market Open.

Truist analyst Robyn Karnauskas lowered the firm’s price target on Pfizer (PFE) to $32 from $36 and keeps a Buy rating on the shares. The firm is reducing its FY25 EPS view by 9c to $2.97 given ...

Wells Fargo raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps an Equal Weight rating on the shares. With better-than-expected EPS guidance largely driven by expense ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PFE surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past month, the stock has declined 4.3% to close the last trading session at $25.58. The average analyst ...